Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00979212 · ClinicalTrials.gov registry record · Phase 2
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
A Phase 2 study of Lung Cancer, sponsored by Radiation Therapy Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 71
- Enrollment target
- 20
- Study locations
NCT00979212 is a Phase 2 study of Lung Cancer that has completed, run by Radiation Therapy Oncology Group. The registered enrollment target is 71 participants, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (92% lower). The trial reports 20 study locations across 13 states.
The verdict
NCT00979212, a Phase 2 study of Lung Cancer, has completed, sponsored by Radiation Therapy Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 71 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy (CT), such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy (RT) uses high-energy x-rays to kill tumor cells. Monoclonal antibodies, such as panitumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving these treatments before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. It is not yet known whether chemotherapy and radiation therapy are more effective when given with or without panitumumab in treating patients with non-small cell lung cancer. PURPOSE: This randomized phase II trial is studying chemotherapy and radiation therapy to see how well they work when given with or without panitumumab in treating patients with stage IIIA non-small cell lung cancer.
Conditions Studied
Interventions
- DRUG carboplatin
- DRUG panitumumab
- DRUG paclitaxel
- PROCEDURE surgery
Study Locations (20)
Maryland
- Greenebaum Cancer Center at University of Maryland Medical Center - Baltimore
- St. Agnes Hospital Cancer Center - Baltimore
- Cancer Institute at St. Joseph Medical Center - Towson
Ohio
- Summa Center for Cancer Care at Akron City Hospital - Akron
- Charles M. Barrett Cancer Center at University Hospital - Cincinnati
- Cleveland Clinic Taussig Cancer Center - Cleveland
California
- Mercy Cancer Center at Mercy San Juan Medical Center - Carmichael
- Radiological Associates of Sacramento Medical Group, Incorporated - Sacramento
Minnesota
- Fairview Southdale Hospital - Edina
- Virginia Piper Cancer Institute at Abbott - Northwestern Hospital - Minneapolis
New York
- NYU Cancer Institute at New York University Medical Center - New York
- James P. Wilmot Cancer Center at University of Rochester Medical Center - Rochester
Colorado
- Penrose Cancer Center at Penrose Hospital - Colorado Springs
Kentucky
- Lucille P. Markey Cancer Center at University of Kentucky - Lexington
Louisiana
- CCOP - Ochsner - New Orleans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2011-02 |
| Est. Completion | 2022-05-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00979212
The ClinicalTrials.gov registry entry for NCT00979212 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 71 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (92% lower). The listed sponsor is Radiation Therapy Oncology Group, which has 144 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lung Cancer appearing as the primary indexed condition, and to 4 interventions - of which carboplatin is the first listed.
NCT00979212 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Maryland, Ohio, California.
Frequently Asked Questions
What is clinical trial NCT00979212 about?
NCT00979212 is a clinical study titled "Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer". RATIONALE: Drugs used in chemotherapy (CT), such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy (RT) uses high-energy x-rays to kill tumor cells. Monoclonal antibodies, such as ...
What is the current status of trial NCT00979212?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 71 participants. The study started on 2011-02. Estimated completion is 2022-05-20.
What conditions does trial NCT00979212 study?
This clinical trial studies the following conditions: Lung Cancer.
What interventions are being tested in trial NCT00979212?
The interventions under investigation include: carboplatin (DRUG), panitumumab (DRUG), paclitaxel (DRUG), surgery (PROCEDURE).
Who is sponsoring clinical trial NCT00979212?
This trial is sponsored by Radiation Therapy Oncology Group, which has 144 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00979212 being conducted?
This trial has 20 study locations across California, Colorado, Kentucky, Louisiana, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Novel Treatment Combinations in Patients With Lung Cancer
RECRUITING · Phase 2
-
Feasibility Study to Treat Lung Cancer With the Permanently Implantable LDR CivaSheet®
RECRUITING · Phase 2
-
ATATcH Alternating Treatment Plans for Advanced Cancer
RECRUITING · Phase 2
-
A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
-
Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.